Recent developments in regulating the pharmaceutical business in the EU

Earl-Slater, Alan

doi:10.1108/09555349610107032

Cited by 9 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although these policy moves may be welcome by some in the industry they represent a narrow interpretation of the value of the industry. A cost‐effective drug does not imply a cost‐effective drug industry[28]. Therefore policy makers must begin to realize the wider and longer term consequences of their policies on drugs bills.…”

Section: Discussionmentioning

confidence: 99%

Can we afford to lose the pharmaceutical industry in the EU?

Earl-Slater

1996

European Business Review

Self Cite

View full text Add to dashboard Cite

Suggests that the population of the EU will still need drugs whether or not the EU continues to have a pharmaceutical industry. Various policies trying to control health service drugs bills have affected the drugs industry: increasingly the effects are adverse. The EU Commission is now taking an increasing interest in health care and pharmaceutical industry policy. It is therefore of some urgency to open the debate up by beginning to signal what the EU stands to lose if it loses the pharmaceutical industry in the EU. Although it is highly improbable that the EU will lose all the present pharmaceutical industry in the EU it is likely that it will lose some of it in the next five years, and it is almost certain that the industry in the EU will continue to yield with respect to industry in North America, the Pacific Basin and Asia.

show abstract

Section: Discussionmentioning

confidence: 99%

Can we afford to lose the pharmaceutical industry in the EU?

Earl-Slater

1996

European Business Review

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the pharmaceutical industry an analysis of the brand manager's role is even more crucial. As a result of changes in the environment, the removal of trade barriers, changes in the legislation in the European Union and the launch of more global drugs (Chaudhry et al, 1994, Earl-Slater, 1996b1997;1998), national protection of the Greek pharmaceutical industry has altered. The effort to control health service drugs bills in the European Union influences the pharmaceutical sector (Earl-Slater, 1996a) and can affect the way that these products are marketed.…”

Section: Developing Proposalsmentioning

confidence: 99%

Brand managers in the pharmaceutical industry: are they any different?

Panigyrakis

Veloutsou²

1999

Journal of Product &Amp; Brand Management

View full text Add to dashboard Cite

This paper examines the brand managers' characteristics and their role in the pharmaceutical industry. It identifies the similarities and differences of that role with the role of brand managers working in the fast-moving consumer goods industry. In particular, this study investigates brand managers' duties, by analysing their perceived involvement in activities relevant to market analysis, planning, implementation, evaluation and training and strategic and tactical decision making. The results proved that brand managers working in various sectors have a co-ordinating role and that their involvement in the strategic decision of their brands is still limited. They also indicated a dissimilarity in the perceived job responsibilities between the two industries.

show abstract

“…(Polidano and Earl-Slater 1994). The Commission's new powers will not be exercised without controversy, part ofwhich will come from the pharmaceutical industry and part from member states (Earl-Slater 1996).…”

Section: Market En@mentioning

confidence: 99%

A Social‐symbiotic Approach? EU Industrial Policy and the Pharmaceutical Industry in the EU

Earl-Slater¹

1996

Soc Policy Adm

View full text Add to dashboard Cite

The purpose ofthis paper is to develop the debate about a symbiotic approach to industrial policy with respect to the Pharmaceutical industry in the EU. The EU has an increasingh important role to p l y in European markets but it seems, at best, to be following a fragmented industrial strategy. There is a real and growing danger that this strategy becomes worsefor everyone than no strategy at all. Thus the EU can eithergo for a comprehensive and comprehensible strategy or let the industry fend f o r itseGf amongst disparate health care systems amongst member states. Alternative& it can continue to stumble along with a pastiche ofpolicies. There are .r@ns of some debate about a more holistic approach to industry. In the European Union for example D G (Directorate General) V and DG III produced a communication arguing that "the [European Union] Community policy in favour of the pharmaceutical industry must take notice of [the] twofold context of public health and social security" This paper ident$es current fragments of EU pharmaceutical industrial policy and indicates what a social-symbiotic approach is. Whether or not the industry in the EU continues to decline with respect to the industry elsewhere Asia and America in particular, the sick people of the EU will still need medication: a symbiotic approach to industrialpolicy can help stem the relative decline in the EU and indeed could reverse it. (Corn (93)718:3).

show abstract

Recent developments in regulating the pharmaceutical business in the EU

Cited by 9 publications

References 19 publications

Can we afford to lose the pharmaceutical industry in the EU?

Can we afford to lose the pharmaceutical industry in the EU?

Brand managers in the pharmaceutical industry: are they any different?

A Social‐symbiotic Approach? EU Industrial Policy and the Pharmaceutical Industry in the EU

Contact Info

Product

Resources

About